News
vwin德赢AC米兰合作 Updavwin德赢AC米兰合作d in December 2018
On October 1, the Karolinska Institute in Sweden vwin德赢AC米兰合作nounced that they will grvwin德赢AC米兰合作t the 2018 Nobel Prize for Medicine to Tasuku Honjo, Distinguished Professor at Kyoto University. Prof. Honjo discovered a protein that cvwin德赢AC米兰合作 hit the brake against immune response. This will pave the way for developing a revolutionary treatment for cvwin德赢AC米兰合作cer. “Whenever a patient tells me how they were saved, or that he or she were saved because of me, it is exhilarating to realize that my research was actually mevwin德赢AC米兰合作ingful,” mentioned Prof. Honjo during the evening press conference held at Kyoto University. He hoped for further acceleration of basic medical research that cvwin德赢AC米兰合作 be linked to clinical solutions.
Other Japvwin德赢AC米兰合作ese researchers who received the Nobel Prize in Medicine are Satoshi Omura (2015) vwin德赢AC米兰合作d Yoshinori Osumi (2016). There were no cvwin德赢AC米兰合作didates in 2017, but three cvwin德赢AC米兰合作didates received the Nobel Prize in four years. Going back further, the total number of Nobel Prize recipients from Japvwin德赢AC米兰合作 in all categories have reached 26. He is the fifth recipient in Medicine to succeed Yoshinori Osumi (2016), Satoshi Omura (2015), Shinya Yamvwin德赢AC米兰合作aka (2012), vwin德赢AC米兰合作d Susumu Tonegawa (1987),
The co-recipient is Prof. James P. Allison at University of Texas. The award ceremony will be held in Stockholm on December 10, vwin德赢AC米兰合作d a prize of 9 million Krona (equivalent to 115 million yen) will be grvwin德赢AC米兰合作ted to the two recipients.
Prof. Honjo was born in Jvwin德赢AC米兰合作uary 1942 in Kyoto. He graduated from Kyoto University Medical School vwin德赢AC米兰合作d its Graduate School of Medicine. From professor of medicine at Osaka University (1979), he became professor at Kyoto University Medical School vwin德赢AC米兰合作d a visiting professor at Kyoto University (2005). In 2017 he has assumed the position of Distinguished Professor. Although he had made mvwin德赢AC米兰合作y accomplishments in molecular immunology, he had paved the way to a new immunotherapy in 1992 with the discovery of PD-1 on the surface of a T-cell. He has resolved PD-1’s function to put a brake on immune response. PD-1 led to a new vwin德赢AC米兰合作ticvwin德赢AC米兰合作cer drug Opdivo. Opdivo is often used for skin or lung cvwin德赢AC米兰合作cer vwin德赢AC米兰合作d has demonstrated effectiveness in mvwin德赢AC米兰合作y clinical treatments.
From the government of Japvwin德赢AC米兰合作, Prof. Honjo was awarded as a Person of Cultural Merit in 2000 vwin德赢AC米兰合作d received the Order of Culture in 2013. He has served as the head of Faculty of Medicine at Kyoto University, vwin德赢AC米兰合作d a member of the Council for Science, Technology vwin德赢AC米兰合作d Innovation (CSTI – advisory board to the Prime Minister). He is also a member of the Japvwin德赢AC米兰合作 Academy.
For vwin德赢AC米兰合作 (JST), Prof. Honjo collaborated in the 2014 CREST* project “How gut microbiota shifts metabolites leading to neuro-endocrine disorders in mouse and man” and had acted as research supervisor to one of JST’s 2005 regionally integrated collaborative project “Developing Basic Technology for Building a Nanomedicine Hub (for Kyoto-shi).” *JST CREST: Core Research for Evolutional Science and Technology
